We are live on
!
Find out more
CCM
CAAS Capital Management Portfolio holdings
AUM
$934M
1-Year Est. Return
1.45%
This Fund
S&P 500
This Quarter
Est. Return
+26.63%
1 Year Est. Return
+1.45%
3 Year Est. Return
+10.99%
5 Year Est. Return
+150.62%
10 Year Est. Return
–
AUM
$10.5B
AUM Growth
+$6.2B
(+145%)
Cap. Flow
+$4.78B
Cap. Flow
% of AUM
45.54%
Top 10 Holdings %
Top 10 Hldgs %
28.07%
Holding
985
New
521
Increased
87
Reduced
60
Closed
171
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$153M |
| 2 |
Sunrun
RUN
|
+$94.3M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$83.8M |
| 4 |
Dynatrace
DT
|
+$67.2M |
| 5 |
Consolidated Edison
ED
|
+$56.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Solar
FSLR
|
+$71.8M |
| 2 |
10x Genomics
TXG
|
+$62.3M |
| 3 |
Caesars Entertainment
CZR
|
+$60.8M |
| 4 |
Denali Therapeutics
DNLI
|
+$53.1M |
| 5 |
PENN Entertainment
PENN
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.01% |
| 2 | Healthcare | 6.25% |
| 3 | Communication Services | 2.7% |
| 4 | Consumer Discretionary | 2.07% |
| 5 | Financials | 1.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Arcus Biosciences
RCUS
$3.47B
| – | – |
-280,837
| Closed | -$4.81M |
|
902
Replimune Group
REPL
$1B
| – | – |
-80,614
| Closed | -$1.86M |
|
903
Rocket Companies
RKT
$38.7B
| – | – |
-962,546
| Closed | -$19.2M |
|
|
RNAM
904
DELISTED
Avidity Biosciences
RNAM
| – | – |
-15,000
| Closed | -$422K |
|
905
Repay Holdings
RPAY
$343M
| – | – |
-977,769
| Closed | -$23M |
|
|
RPTX
906
DELISTED
Repare Therapeutics
RPTX
| – | – |
-50,000
| Closed | -$1.54M |
|
907
Revolve Group
RVLV
$1.86B
| – | – |
-424,588
| Closed | -$6.98M |
|
908
Rackspace Technology
RXT
$1.21B
| – | – |
-504,100
| Closed | -$9.72M |
|
909
Steven Madden
SHOO
$3.48B
| – | – |
-127,534
| Closed | -$2.49M |
|
910
SLB Ltd
SLB
$73.2B
| – | – |
-120,000
| Closed | -$2.26M |
|
911
SelectQuote
SLQT
$133M
| – | – |
-300,000
| Closed | -$6.08M |
|
912
Stewart Information Services
STC
$2.1B
| – | – |
-6,427
| Closed | -$281K |
|
913
CALL
Stellantis
STLA
$21.3B
| – | – |
-400,000
| Closed | -$4.89M |
|
914
Target Hospitality
TH
$1.57B
| – | – |
-47,232
| Closed | -$58K |
|
915
Tesla
TSLA
$1.27T
| – | – |
-3,225
| Closed | -$550K |
|
|
916
10x Genomics
TXG
$5.97B
| – | – |
-499,456
| Closed | -$62.3M |
|
917
CALL
United Parcel Service
UPS
$90.8B
| – | – |
-185,000
| Closed | -$30.8M |
|
918
CALL
US Bancorp
USB
$99.6B
| – | – |
-6,700
| Closed | -$240K |
|
919
Veracyte
VCYT
$3.58B
| – | – |
-127,905
| Closed | -$4.16M |
|
920
Vital Farms
VITL
$548M
| – | – |
-70,000
| Closed | -$2.84M |
|
921
Vulcan Materials
VMC
$36.7B
| – | – |
-7,579
| Closed | -$1.08M |
|
922
Vroom Inc
VRM
$37.2M
| – | – |
-1,207
| Closed | -$5M |
|
|
VSTA
923
DELISTED
Vasta Platform
VSTA
| – | – |
-200,000
| Closed | -$3.09M |
|
924
Western Digital
WDC
$182B
| – | – |
-41,530
| Closed | -$1.38M |
|
|
GAP
925
CALL
The Gap Inc
GAP
$7.38B
| – | – |
-500,000
| Closed | -$8.52M |
|
Similar funds
CIG
TAM
WCF
CHP
SWC
KTA
LC
SBIA
CAAS Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, CAAS Capital Management held 985 positions worth $10.5B, up 145% from $4.29B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
CAAS Capital Management deployed $4.78B of net new capital in Q4 2020, opening 521 new positions and adding to 87 existing holdings. Its largest new stake was Sunrun: 1,519,346 shares worth $105M.
By sector, the portfolio is most concentrated in Technology at 7% of assets, down from 7.8% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was First Solar, an estimated $71.8M trimmed.
- CAAS Capital Management's largest Q4 2020 buy was Sunrun: 1,519,346 shares worth $105M.
- CAAS Capital Management added most to Royalty Pharma in Q4 2020, an estimated $153M increase.
- CAAS Capital Management's biggest Q4 2020 reduction was First Solar, cutting an estimated $71.8M.
- CAAS Capital Management fully exited 10x Genomics in Q4 2020, selling an estimated $62.3M.
- CAAS Capital Management's ten largest holdings make up 28% of its $10.5B portfolio in Q4 2020.
- CAAS Capital Management opened 521 new positions and closed 171 in Q4 2020.
- CAAS Capital Management's portfolio value rose 145% quarter-over-quarter to $10.5B.
Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.